MOLOGEN closes License Agreement with Major Animal Health Company on MIDGE-based Vaccine for Companion Animal Application

MOLOGEN AG (ISIN DE0006637200) has finalized a research and development, collaboration and license agreement with one of the top 10 animal health companies. The company is a division of a large, global human pharmaceutical company based in the United States. The agreement governs final clinical development, licensing, and marketing of MOLOGEN's MIDGE-based vaccine against Leishmaniasis for a companion animal application. It is agreed to keep in confidence further contract details.

According to the agreement, MOLOGEN will receive from the veterinary pharmaceutical company an initial payment upon execution of the agreement, future payments for milestones achieved, and a royalty on sales. Marketing of the MIDGE vaccine will initially target European markets where Leishmaniasis is a widespread disease in companion animals.

About MOLOGEN

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview